• Manju Mamtani, Hemant Kulkarni, Shailesh Bihari, Shivesh Prakash, Shaila Chavan, Sue Huckson, and David Pilcher.
• M&H Research, LLC, San Antonio, TX, USA. Electronic address: manju.mamtani@mnhresearch.com.
• J Crit Care. 2020 Feb 1; 55: 149-156.

PurposeHyperglycemia (HG) in critically ill patients influences clinical outcomes and hospitalization costs. We aimed to describe association of HG with hospital mortality and length of stay in large scale, real-world scenario.MaterialsFrom The Australian and New Zealand Intensive Care Society (ANZICS) Adult Patient Database (APD) we included 739,152 intensive care unit (ICU) patients admitted during 2007-2016. Hyperglycemia was quatified using midpoint blood glucose level (MBGL). Association with outcomes (hospital mortality and length of stay (LOS)) was tested using multivariable, mixed effects, 2-level hierarchical regression.ResultsDegree of HG (defined using MBGL as a continuous variable) was significantly associated with hospital mortality and longer hospital stay in a dose-dependent fashion. The fourth, third and second MBGL (compared to the first) quartiles were associated with hospital mortality (odds ratio 1.34, 1.05 and 0.97, respectively) and longer hospital stay (1.56, 1.38 and 0.93 days, respectively). These associations were stronger associations in trauma (especially head injury), neurological disease and coma patients. Significant variation across ICUs was observed for all associations.ConclusionsIn this largest study of nondiabetic ICU patients, HG was associated with both study outcomes. This association was differential across ICUs and diagnostic categories.Copyright © 2019 Elsevier Inc. All rights reserved.

28 keywords...

hide…